MedTrace Logo

CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)

NCT02515942 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2019-05-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of 12 (every 28 days) intravitreal (IVT) injections of CLG561 as a monotherapy and in combination with LFG316 as compared to sham in subjects with geographic atrophy.

Conditions

Interventions

DRUG

CLG561

DRUG

LFG316

DRUG

Sham injection

Empty syringe (without a needle) placed against the eye

Sponsors & Collaborators

  • Novartis Institutes for BioMedical Research

    collaborator OTHER

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Sr Clinical Manager, Pharma, GCRA · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-25
Primary Completion
2017-08-14
Completion
2017-12-01
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02515942 on ClinicalTrials.gov